A benefits leader once told me their GLP-1 program was a success. Engagement was up. Employees were losing weight. Internally, everyone was celebrating.
Then someone asked the question that kills every premature victory lap in healthcare: “How do we prove this is actually working?”
Not weight loss. Not engagement scores. Real, sustained impact on health and cost of care. The room got quiet.
That silence is where the industry lives right now.
GLP-1s changed everything. And nothing.
In Mercer’s 2026 benefits survey, 77% of large employers said managing GLP-1 costs was extremely or very important. The demand is real. The results are real. So is the bill: GLP-1 costs now comprise around 20% of total prescription drug spend, and total GLP-1 spend increased roughly 50% in 2025 alone. Among large employers with 5,000 or more workers, 66% reported GLP-1 coverage had a significant impact on prescription drug spending.
And the harder questions are starting to surface. What happens when patients stop? Data from Prime Therapeutics shows only 1 in 12 members remain on treatment after three years. Are we improving health, or just changing a number on a scale?
Here is the uncomfortable truth: we have been solving the wrong problem.
Weight is a symptom. We have been treating the symptom.
Metabolic health, specifically how the body regulates glucose, cardiovascular function, energy, and muscle mass over time, is the actual disease. It determines whether a patient progresses toward diabetes, heart failure, or a decade of expensive chronic care management.
Weight loss does not guarantee any of that improves. And the research is sharpening this point considerably. Clinical trials show lean soft tissue loss comprising 26% to 40% of total weight loss in patients taking semaglutide or tirzepatide. Rapid weight reduction with GLP-1 drugs can lead to 15 to 25% lean muscle mass loss, which lowers metabolic rate, reduces physical strength, and raises longer-term health risks, particularly in aging workforces.
Patients can drop BMI without touching cardiovascular risk. They can discontinue medication and regain everything within months. From a clinical standpoint, that is incomplete. From an employer standpoint, it is a liability.
GLP-1s are extraordinary. They are also not a complete solution. They never were.
The shift that is already happening
The most forward-thinking employers and digital health organizations have figured this out. They are not abandoning GLP-1s. They are building around them.
The programs getting results have expanded their aperture. From weight to body composition. From point-in-time snapshots to longitudinal trends. From medication alone to continuous, supported care that tracks what actually drives long-term outcomes.
This is not idealism. It is economics. Employers are projecting a median 9% healthcare cost increase in 2026, driven in significant part by obesity medication utilization. They are asking sharper questions than they were two years ago: Are we reducing total cost of care or just adding a new cost category? Are results sustainable when medication stops? Are we moving the right needles?
These are business questions now. And they demand business-grade answers.
The gap no one wants to talk about
The biggest failure in today’s programs is not access to medication. It is the void between clinical interactions.
Without continuous data, care teams are flying blind. Is the patient adhering? Are they losing fat or muscle? Is cardiovascular risk improving or quietly worsening? Are there early signs of relapse before relapse becomes the outcome?
Programs without this visibility operate reactively. Interventions arrive too late. Outcomes are hard to measure and nearly impossible to defend to a CFO staring at a $1,000 per month drug spend with no proof of downstream impact.
Aon’s January 2026 multi-year study of over 192,000 GLP-1 users found that sustained adherence is the single biggest driver of both health outcomes and cost savings, but that consistent use is the exception, not the rule. Continuous monitoring is what makes adherence visible and actionable.
It transforms programs from episodic to longitudinal. That is not a subtle distinction. It is the whole game.
A higher bar. The only bar that matters.
We are watching a market mature in real time.
The employers who treat GLP-1 coverage as the finish line will face escalating costs, inconsistent outcomes, and programs they cannot defend. The ones building toward metabolic health platforms, combining medication, body composition monitoring, behavioral support, and continuous data, will build something that actually works.
The organizations that get this right will reduce chronic disease burden, lower long-term cost trajectories, and deliver the one thing every benefits leader ultimately needs: proof.
Not engagement metrics. Not weight charts. Proof that their investment improved health.
GLP-1s opened the door. But they are not the destination. The future of employer health programs will not be defined by how many employees lose weight. It will be defined by how effectively organizations improve metabolic health, sustainably, measurably, at scale.
That is a harder problem. It requires better data, more integrated care models, and partners willing to be accountable for outcomes rather than just activity.
But it is also the only standard that truly matters. And the employers who adopt it first will not just outperform their peers on health outcomes. They will outperform them on cost. Full stop.